Maxcyte (MXCT) Revenue (2020 - 2026)

Maxcyte (MXCT) has 7 years of Revenue data on file, last reported at $4.5 million in Q1 2026.

• On a quarterly basis, Revenue fell 56.68% year-over-year to $4.5 million in Q1 2026; TTM through Mar 2026 was $15.1 million, a 49.05% decrease from a year earlier, with the FY2025 full-year figure at $21.0 million, down 5.66% from the prior year.
• Revenue for Q1 2026 stood at $4.5 million, up from -$4.8 million in the prior quarter.
• Over the last five years, Revenue for MXCT reached as high as $26.5 million in Q4 2023 and fell as low as -$4.8 million in Q4 2025.
• Historically, Revenue has averaged $7.9 million across 5 years, with a median of $7.8 million in 2022.
• Across the five-year window, Revenue surged 242.27% in 2023 and sank 178.76% in 2025, its largest moves.
• Year by year, Revenue stood at $7.8 million in 2022, then jumped by 242.27% to $26.5 million in 2023, then sank by 77.19% to $6.1 million in 2024, then plunged by 178.76% to -$4.8 million in 2025, then jumped by 194.38% to $4.5 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $4.5 million in Q1 2026, -$4.8 million in Q4 2025, and $6.8 million in Q3 2025.